O-THIOCARBAMOYL-AMINOALKANOL COMPOUNDS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR PREPARING THE SAME

Abstract: The present invention relates to O-thiocarbamoyl-aminoalkanol compound represented by structural formula (VI) which are a racemic or enantiomerically enriched and pharmaceutically acceptable salts thereof to treat diseases of the central nervous system: wherein Ar is a phenyl group as described in formula (1): wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, CI, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. R1 and R2 and R3 and R4 respectively may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R3 and R4, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, each of 1, m and n is zero or 1, and the pharmaceutically acceptable salts thereof.

Description: O-THIOCARBAMOYL-AMTNOALK ANOT COMPOUNDS. THETR PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR PREPARING THE SAME. BACKGROUND OF THE INVENTION Field ofthe Invention The present invention relates, in general, to novel thiocarbamates of aminoalkanols and pharmaceutically useful salts thereof, useful in the treatment of the diseases of the central nervous system. More particularly, the present invention relates to racemic mixture or enantiomerically enriched O-thiocarbamoyl- aminoalkanol compounds and pharmaceutically useful salts thereof, processes for their production, compositions thereof and methods of treating central nervous system disorders. Description of the Prior Art Phenylethylamine derivatives, one important class of therapeutical medicines useful in managing central nervous system (CNS) diseases, have been used mainly to treat obesity, narcolepsy, minimal brain dysfunction and mild depression. Organic thiocarbamates or carbamates have been effectively used for controlling various CNS disorders. For example, U.S. Pat. No. 2,901,501 discloses 1,3- dithiocarbamoyl-l,3-propanediols that are further substituted at position-2 with hydrocarbon based moieties that include aryl groups. J. Am. Chem. Soc, 73, 5779 (1951) discloses 2-methyl-2-propyl-l,3-propandiol dicarbamate and its pharmaceutical activity was verified in J. Pharmacol. Exp. Ther., 104, 229 (1952). Besides, there are many carbamate compounds that are suggested as therapeutics for CNS disease in the prior art. For example, U.S. Pat. Nos. 2,884,444 and 2,937,119 disclose carbamates, such as 2-phenyl-l,3-propandiol dicarbamate and isopropylmeprobamate, respectively. These compounds are found to be very effectively used as therapeutics for treating CNS disorders, especially as antiepileptic and centrally acting muscle relaxants. Research in the development of thiocarbamate or carbamate therapeutics for CNS diseases has been and continues to be actively advanced. Recent design of pharmacologically useful compounds has been based on amino acids or the derivatives thereof, which is mainly attributable to the fact that many ofthe compounds found in biological systems come from amino acids or the derivatives thereof. In addition, in most cases, the function of a pharmaceutically useful compound is effected after it binds to an enzyme or receptor, which may trigger the regulatory mechanisms ofthe enzyme or receptor. SUMMARY OF THE INVENTION As a result of intensive and thorough research, it has been found that O- thiocarbamoyl-aminoalkanol compounds are pharmaceutically useful for CNS disorders, especially for depression and anxiety. Accordingly, it is a principal object of the present invention to provide racemic O-thiocarbamoyl-aminoalkanol compounds, represented by the following general structural formula (VI): wherein Ar is a phenyl group as described as followings: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl from 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Rj and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atom directly unconnected. R 3 and j may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl from 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and R4, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atom directly unconnected. Each of 1, m and n is zero or 1, and the pharmaceutically acceptable salts thereof. It is also a principal object of the present invention to provide O-thiocarbamoyl- (D)-aminoalkanol compounds, represented by the following structural formula VIII: (alternatively, "D" can be referred to as the R-configuration at the chiral center in structural formula VIII) wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Ri and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl from 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R] and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected. R 3 and Rj may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl from 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and R_ι, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atom directly unconnected. Each of 1, m and n is zero or 1, and the pharmaceutically acceptable salts thereof. It is also a principal object ofthe present invention to provide O-thiocarbamoyl- (L)-aminoalkanol compounds, represented by the following structural formula IX: (alternatively, "L" can be referred to as the S-configuration at the chiral center in structural formula (IX) wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which may comprise zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atom directly unconnected. R 3 and ^ may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and R 4 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which may comprise zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atom directly unconnected. Each of 1, m and n is zero or 1 , and the pharmaceutically acceptable salts thereof. DETAILED DESCRIPTION OF THE INVENTION In accordance with the present invention, the racemic or enantiomerically enriched O-thiocarbamoyl-aminoalkanols represented by the structural formula VI, VIII and IX and pharmaceutically acceptable salts thereof can be prepared by the following steps starting from readily available starting materials represented by the following general structural formula II: wherein Ar is the same as defined above. It should be noted that the stereochemistry ofthe final products (VI, VIII and IX) depend solely on that of the starting material (II); a starting material (II) with an D- enantiomer yields only a product with D-enantiomer (VIII) and a starting material (II) with an L-enantiomer yields only a product with L-enantiomer (IX) The first method for preparing the novel compounds of the general formula VI in which R 3 =R4=H or R}=H will be described below in detail. Initially, aminoalkanol (II) is reacted with Di-t-butyl dicarbonate to synthesize N-t-butyloxycarbonyl-aminoalkanol represented by the general formula (III). This is followed by the treatment with sodium hydride, carbon disulfide and methyl iodide in an ethereal solution which is followed by the treatment with an amine base (IV) to yield O-thiocarbamoyl-N-t-butyloxycarbonyl- aminoalkanol represented by the general formula (V): wherein Ar, Ri, R 2 , R 3 ' R 4 , 1, m and n are as defined above and Boc represents t- butyloxy carbonyl radical . Then, this intermediate is deprotected by aqueous hydrochloric acid solution. As a result of the deprotection, there is obtained O- thiocarbamoyl-aminoalkanol represented by the general formula VI. Without further purification, the compound of formula VI may be converted into pharmaceutically acceptable salts (I) as described above. This procedure is summarized as set forth in Reaction Scheme I below. Reaction Scheme I (II) (III) Boc = C(0)0-t-Butyl (V) (VI) Details of the reaction conditions described in Reaction Scheme I are as follows. In the first step, the concentration ofthe starting material (II) is about 0.005 to 3 moles with di-t-butyl dicarbonate ranging from about 1.0 to 2.0 equivalents. The basic aqueous solution has a pH value between about 7 and 14 and the conversion is carried out at temperature from about -10 to 70 °C. For the conversion of the compound (III) to the compound (IV), sodium hydride and carbon disulfide ranging from about 1.0 to 2.0 equivalents and methyl iodide ranging from about 1.0 to 2.5 equivalent is used and is preferably carried out at a temperature of about -10 to 70 °C. Without purification, the resulting intermediate is treated with 1 to 5 equivalents of amine at a temperature of about -10 to 30 °C, to give the compound of the general formula (V). For this thiocarbamoylation, an ethereal solvent, such as diethyl ether and tetrahydrofuran, or a polar aprotic solvent, such as dimethylformamide and dimethyl sulfoxide, is employed. The compound ofthe general formula (VI) (0.005 to 3 moles) is treated with aqueous 1 to 12 N hydrochloric acid at a temperature of about -10 to 30 °C, followed by neutralization. In the Reaction Scheme I, HX represents an acid capable of forming a pharmacologically useful salt with the basic nitrogen atom. Specific examples of the anhydrous acid used for the preparation of the compound (I) from the compound (VI) include hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, benzoic acid, citric acid, malonic acid, salicylic acid, malic acid, fumaric acid, oxalic acid, succinic acid, tartaric acid, lactic acid, gluconic acid, ascorbic acid, maleic acid, aspartic acid, benzene sulfonic acid, methane sulfonic acid, ethane sulfonic acid, hydroxymethane sulfonic acid and hydroxyethane sulfonic acid and the like. Additional acids can refer to "Pharmaceutical Salts", J. Pharm. Sci., 1977; 66 (1): 1-19. This preparation is executed in a reaction media which can be exemplified by an ethereal solvent such as THF, an alcoholic solvent such as methanol, an ester solvent such as ethyl acetate, an aromatic solvent, and any compositional mixture thereof. An ethereal solvent is recommended as an addition solution, including ethyl ether, propyl ether, isopropyl ether, butyl ether, isobutyl ether. The concentration of the compound (VI) is on the order of about 0.01 to 5 mole. The second method for preparing the novel compounds of the general formula (VI) in which R 3 and R_t are not hydrogen will be described in detail below. Initially, aminoalkanol (II) is reacted with sodium hydride, carbon disulfide and methyl iodide in an ethereal solution resulting in a xanthate which is , then, treated with an amine base (IV) to yield O-thiocarbamoyl- aminoalkanol represented by the general formula (VI) wherein Ar, Rj, R 2 , R 3 - *, 1, m and n are as defined above. Without further purification, the compound of formula (VI) may be converted into pharmaceutically acceptable salts (I) as described above. This procedure is summarized as set forth in Reaction Scheme II below. Reaction Scheme II (II) (VI) Details ofthe reaction conditions described in Reaction Scheme I are as follows. In the first step, for the conversion ofthe compound (II) to the compound (VI), sodium hydride and carbon disulfide ranging from about 1.0 to 2.0 equivalents and methyl iodide ranging from about 1.0 to 2.5 equivalents is used and is preferably carried out at a temperature of about -10 to 70 °C. Without purification, the resulting intermediate is treated with 1 to 5 equivalents of amine(IV) at a temperature of about -10 to 30 °C, to give the compound of the general formula (VI). For this thiocarbamoylation, an ethereal solvent, such as diethyl ether and tetrahydrofuran, or a polar aprotic solvent ,such as dimethylformamide and dimethyl sulfoxide, is employed. The compound of the general formula (VI) (about 0.005 to 3 moles) is treated with aqueous 1 to 12 N hydrochloric acid at a temperature of about -10 to 30 °C, followed by neutralization. In the Reaction Scheme II, HX represents an acid capable of forming a pharmacologically useful salt with the basic nitrogen atom. The third method for preparing the novel compounds ofthe general formula (VI) in which Rι=R 3 = R_j = H or R^P = H will be described in detail below. Initially, reacting N-(t-butyloxycarbonyl)-aminoalkanol (III) with isothiocyanate (VII) yields a N-(t-butyloxycarbonyl)-O-thiocarbamoyl-aminoalkanol represented by the general formula (V): wherein Ar, Ri, R 2 , R 3 , 1, m and n are as defined above and Boc repressants t- butyloxy carbonyl radical . Then, this intermediate is deprotected by aqueous hydrochloric acid solution. As a result of the deprotection, there is obtained O- thiocarbamoyl-aminoalkanol represented by the general formula (VI). Without further purification, the compound of formula (VI) may be converted into pharmaceutically acceptable salts (I) as described above. This procedure is summarized as set forth in Reaction Scheme III below. Reaction Scheme III (VI) (I) Details of the reaction conditions described in Reaction Scheme III are as follows. In the second step, the concentration of the starting material (III) is about 0.005 to 3 moles with isothiocyanate (VII) ranging from about 1.0 to 2.0 equivalents. The conversion is carried out at temperature from about 30 to 110 °C. For this thiocarbamoylation, an ethereal solvent such as diethyl ether and tetrahydrofuran, a halogenated hydrocarbon solvent, such as dichloromethane and chloroform or an aromatic solvent, such as benzene and toluene may be used, with the halogenated hydrocarbon solvent, such as dichloromethane and chloroform being preferred. The compound of the general formula (VI) (about 0.005 to 3 moles) is treated with aqueous 1 to 12 N hydrochloric acid at a temperature of about -10 to 30 °C, followed by neutralization. The fourth method for preparing the novel compounds of the general formula (VI) in which R 3 and R» are not hydrogen and Ri is hydrogen will be described in detail below. Initially, aminoalkanol (II) is reacted with isothiocyanate (VII) in a halogenated hydrocarbon solvent to yield a O-thiocarbamoyl-aminoalkanol represented by the general formula (VI): wherein Ar, Ri, R 2 , R 3 , 1, m and n are as defined above. Without further purification, the compound of formula (VI) may be converted into pharmaceutically acceptable salts (I) as described above. This procedure is summarized as set forth in Reaction Scheme IV below. Reaction Scheme IV (II) (VI) Representative examples ofthe compounds (VI), (VIII) and (IX) from Reaction Scheme I, II, III and IV are shown in Table I: Table I. Examples ofthe compound (VI), (VIII) and (IX) from Reaction Scheme I , II, III and IV For therapeutic use in medicines for treating pain, depression, anxiety, epilepsy, stroke, demential and Parkinson's disease, the compounds of the present invention, alone or in combination with a pharmaceutically acceptable carrier, are administered to patients at a dosage of from about 0.7 to 7,000 mg per day. For a normal human adult with a body weight of approximately 70 kg, the administration amount is translated into a daily dose of about 0.01 to 100 mg per kg of body weight. The specific dosage employed, however, will vary depending upon the requirements of the patient, the severity of the patient's condition and the activity of the compound. The determination of optimum dosages for a particular situation must be determined clinically and is within the skill ofthe art. In utilizing the compounds ofthe present invention for the treatment of disorders and diseases of the central nervous system, particularly to treat depression, it is preferred to administer the compounds orally. Since the compounds are well-absorbed orally, it usually will not be necessary to resort to parenteral administration. For oral administration, the compound (I) of female is preferably combined with a pharmaceutical carrier. The ratio of the carrier to the compound of Formula (I) is not critical to express the effects ofthe medicine on the central nervous system, and it can vary considerably depending on whether the composition is to be filled into capsules or formed into tablets. In tableting, various edible pharmaceutical carriers or mixtures thereof can be used. Suitable carriers, for example, are a mixture of lactose, diabasic calcium phosphate and/or corn starch. Other pharmaceutically acceptable ingredients can be further added, including lubricants such as magnesium stearate. Besides the compound of Formula (I), compositions comprising it are within the scope ofthe present invention. Furthermore., the present invention includes uses ofthe compound (I) and/or the composition. As described hereinbefore, the compounds represented by Structural Formula I were observed to be useful for the prophylaxis and treatment of CNS disorders including pain, depression, anxiety, epilepsy, stroke, demential and Parkinson's disease. The therapeutic use of the compounds claimed in the present invention as antidepressants has been proven by the "Forced Swimming Test", a well known pharmacological screening methods for depression and the results are shown in the following Table II. The procedure described by Porsolt et al., (1997) was used. Test compound was administered p.o. and i.p. to mice (CD-I strain), one hour prior to the animals being immersed in a 1500mL glass beaker (16.5cm deep, 13.0cm diameter) filled with water (20 ~ 23°C) to about 5cm from the top. Mice were kept in the water for a period of 15 minutes and the duration of immobility observed within the 15 -minute test period was recorded. A mouse was judged to be immobile if it floated motionlessly in the water making only those movements necessary to keep its head above the water. Table II The therapeutic use of the compounds claimed in the present invention as anticonvulsants has been proven by the "Maximal ElectroShock (MES)" test, which is a well-established pharmacological screening method for anticonvulsants against partial seizures, and the results are presented in Table III. The procedure employed in the MES test for anticonvulsants follows. The compound dosing solutions were prepared in saline, and the subject, namely, mice (CD- 1 strain), were dosed orally. After the designated number of hours, maximal electroshock was induced in mice via corneal electrodes using ETC Life Science model 11 A Shocker at 50mA-60Hz for 0.2 second. Upon inducing maximal electroshock, the elimination of hindlimb tonic extension was considered as providing evidence of the protection by an anticonvulsant. Median efficacy dose (ED50) levels were determined using three different dose levels with at least 6 mice in each group. Compounds with smaller ED50 value are more potent as anticonvulsants. Table III A better understanding of the present invention may be obtained in light of following examples which are set forth to illustrate, but are not to be construed to limit, the present invention. Example 1 O-Thiocarbamoyl-N-(t-butyloxycarbonyl)-(DL)-phenylalaninol In a 500mL flask equipped with magnetic stirrer, N-(t-butyloxycarbonyl)-(DL)- phenylalaninol(0.051 mole, 13.6g) was dissolved in 200mL of THF and was added with NaH(0.061 mole, 1.47g) at 0°C. The reaction mixture was stirred at 0°C for 1 hour, followed by the addition of CS 2 (0.061 mole, 4.66g). After being stirred for 40 min. at 0°C, Mel(0.061 mole, 8.69g) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 hours, followed by the addition of 5N NH OH (0.090 mole, 18.0mL) for 6 hours. The resulting solution was quenched with water. The organic layer was extracted 3 times with dichloromethane, dried over magnesium sulfate and distilled in vacuo, to give a solid. This was recrystalized in a solution mixture of n-hexane and diethyl ether, to produce 14.7g of O-thiocarbamoyl-N-(t- butyloxycarbonyl)-(DL)-phenylalaninol: Yield 80%. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 1.35(s,9H), 2.65-2.98(m,2H), 4.05- 4.25(br,lH), 4.33-4.43(m,2H), 4.62-4.83(br,lH), 6.25(s,lH), 6.58(s,lH), 7.01- 7.42(m,5H). Example 2 O-Thiocarbamoyl-N-(t-butyloxycarbonyl)-(L)-phenylalaninol The procedure given in Example 1 was followed using N-(t-butyloxycarbonyl)- (L)-phenylalaninol as a starting material, instead of N-(t-butyloxycarbonyl)-(DL)- phenylalaninol, to give 1.90g ofthe title compound. A yield of 79% was obtained. ! H-NMR(CDC1 3 , 200MHz), ppm(δ) ; 1.38(s,9H), 2.72-2.95(m,2H), 4.01- 4.28(br,lH), 4.30-4.48(m,2H), 4.62-4.83(br,lH), 6.22(s,lH), 6.67(s,lH), 7.08- 7.39(m,5H). Example 3 O-Thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol In a 500mL flask equipped with magnetic stirrer, N-(t-butyloxycarbonyl)-(D)- phenylalaninol(0.040 mole, 10.05g) was dissolved in 200mL of THF and was added with NaH(0.048 mole, 1.15g) at 0°C. The reaction mixture was stirred at 0°C for 1 hour, followed by the addition of CS 2 (0.048 mole, 3.65g). After being stirred for 40 min. at 0°C, Mel(0.048 mole, 6.81g) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 2 hours, followed by the addition of 5N NH 4 OH (0.090 mole, 18.0mL) for 6 hours. The resulting solution was quenched with water. The organic layer was extracted 3 times with dichloromethane, dried over magnesium sulfate and distilled in vacuo, to give a solid. This was recrystalized in a solution mixture of n-hexane and diethyl ether, to produce 11.3g of O-thiocarbamoyl- N-(t-butyloxycarbonyl)-(D)-phenylalaninol: Yield 78%. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 1.45(s,9H), 2.77-3.01(m,2H), 4.01- 4.28(br,lH), 4.30-4.5 l(m,2H), 4.60-4.83(br,lH), 6.25(s,lH), 6.55(s,lH), 7.11- 7.51(m,5H). Example 4 O-(N-Methyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol The procedure given in Example 3 was followed using methylamine as a reactant, instead of NH 4 OH, to give 2.33g of the title compound. A yield of 75% was obtained. ! H-NMR(CDC1 3 , 200MHz), ppm(δ) ; 1.45(s,9H), 2.68-2.98(m,2.5H), 3.12(d,1.5H), 4.06-4.28(br,lH), 4.31-4.55(m,2H), 6.35(br,0.5H), 6.65(br,0.5H), 7.05- 7.48(m,5H). Example 5 O-(N-Cyclopropyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol The procedure given in Example 3 was followed using cyclopropylamine as a reactant, instead of NH 4 OH, to give 2.49g of the title compound. A yield of 74% was obtained. ιH-NMR(CDCl 3 , 200MHz), pρm(δ) ; 0.51-0.98(m,4H), 1.45(s,9H), 2.68- 3.05(m,3H), 4.05-4.82(m,4H), 6.42(br,0.5H), 6.82(br,0.5H), 7.05-7.48(m,5H). Example 6 O-(N-Octyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol The procedure given in Example 3 was followed using n-octylamine as a reactant, instead of NH 4 OH, to give 3.34g of the title compound. A yield of 78%> was obtained. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 0.89(t,3H), 1.02-1.78(m,21H), 2.68- 3.02(m,2H), 3.25(q,lH), 3.52(q,lH), 4.01-4.82(m,4H), 6.45(br,0.5H), 6.95(br,0.5H), 7.05-7.48(m,5H). Example 7 O-(N-Isopropyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol The procedure given in Example 3 was followed using isopropylamine as a reactant, instead of NH 4 OH, to give 3.0g of the title compound. A yield of 80%> was obtained. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 1.12-1.65(m,15H), 2.72-2.955(m,2H), 4.05-4.55(m,3H), 4.65(br,lH), 6.15(br,0.5H), 6.52(br,0.5H), 7.05-7.48(m,5H) Example 8 O-(N-Dimethyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol The procedure given in Example 3 was followed using dimethylamine as a reactant, instead of NH 4 OH, to give 2.56g of the title compound. A yield of 67% was obtained. .H-NMR(CDC1 3 , 200MHz), ppm(δ) ; 1.45(s,9H), 2.78-2.98(m,2H), 3.12(s,3H), 3.38(s,3H), 4.18-4.52(m,3H), 4.58-4.74(br,lH), 7.10-7.38(m,5H). Example 9 O-(N-Morpholino)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol The procedure given in Example 3 was followed using morpholine as a reactant, instead of NH 4 OH, to give 2.97g ofthe title compound. A yield of 75% was obtained. ιH-NMR(CDCl 3 , 200MHz), ρpm(δ) ; 1.45(s,9H), 2.68-2.98(m,2H), 3.55- 3.92(m,6H), 4.01-4.75(m,6H), 7.05-7.48(m,5H). Example 10 O-(N-Methyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(DL)-(o-fluoro) phenylalaninol The procedure given in Example 1 was followed using N-(t-butyloxycarbonyl)- (DL)-(o-fluoro)phenylalaninol as a starting material and methylamine as a reactant, instead of N-(t-butyloxycarbonyl)-(DL)-phenylalaninol and NH 4 OH, to give 1.0 lg of the title compound. A yield of 60%o was obtained. .H-NMR(CDC1 3 , 200MHz), ppm(δ) ; 1.35(s,9H), 2.72-3.15(m,5H), 4.01- 4.28(br,lH), 4.30-4.52(m,2H), 4.58-4.83(br,lH), 6.42(s,lH), 6.71(s,lH), 6.98- 7.32(m,5H). Example 11 O-Thiocarbamoyl-N-(t-butyloxycarbonyl)-(DL)-(p-chloro)phenylalaninol The procedure given in Example 1 was followed using N-(t-butyloxycarbonyl)- (DL)-(p-chloro)phenylalaninol as a starting material, instead of N-(t-butyloxycarbonyl)- (DL)-phenylalaninol, to give 3.0g ofthe title compound. A yield of 62% was obtained. ιH-NMR(DMSO-d 6 ,200MHz), ppm(δ) ; 1.32(s,9H), 2.62-2.82(m,2H), 3.79- 4.01(br,lH), 4.03-4.42(m,3H), 6.98-7.42(m,5H), 8.25(s,lH), 8.65(s,lH). Example 12 O-Thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-(t-butyloxycarbonyloxy) phenylalaninol The procedure given in Example 3 was followed using N-(t-butyloxycarbonyl)- (D)-(t-butyloxycarbonyloxy)phenylalaninol as a starting material, instead of N-(t- butyloxycarbonyl)-(D)-phenylalaninol, to give 2.9g of the title compound. A yield of 60%) was obtained. ! H-NMR(CDC1 3 , 200MHz), ppm(δ) ; 1.18-1.75(m,18H), 2.78-3.01(m,2H), 4.11- 4.25(m,lH), 4.35-4.5 l(m,2H), 4.65-4.85(m,lH), 6.22(br.s,lH), 6.66(br.s,lH), 7.02- 7.35(m,4H). Example 13 O-(N-Dimethyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-(m,p-dichloro) phenylalaninol The procedure given in Example 3 was followed using N-(t-butyloxycarbonyl)- (D)-(m,p-dichloro)phenylalaninol as a starting material and dimethylamine as a reactant, instead of N-(t-butyloxycarbonyl)-(D)-phenylalaninol and NH 4 OH, to give 2.5g ofthe title compound. A yield of 62% was obtained. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 1.28-1.42(m,9H), 2.69-2.88(m,2H), 3.11(d,3H), 3.37(d,3H), 4.09-4.28(m,lH), 4.35-4.5 l(m,2H), 4.61-4.81(m,lH), 7.01- 7.41 (m,3H). Example 14 O-(N-Ethoxycarbonyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)- phenylalaninol In a lOOmL flask equipped with magnetic stirrer, N-(t-butyloxycarbonyl)-(D)- phenylalaninol(0.013 mole, 3.3g) was dissolved in 50mL of chloroform and was added with ethoxycarbonyl isothiocyanate(0.014 mole, 1.7mL) at room temperature. The reaction mixture was heated under reflux for 6 hours and then cooled to room temperature. The resulting solution was quenched with water. The organic layer was extracted 3 times with dichloromethane, dried over magnesium sulfate and distilled in vacuo, to give a solid. This was recrystalized in a solution mixture of n-hexane and diethyl ether, to produce 2.56g of O-(N-ethoxycarbonyl)thiocarbamoyl-N-(t- butyloxycarbonyl)-(D)-phenylalaninol. A yield of 56%> was obtained. ]H-NMR(CDC1 3 , 200MHz), ρρm(δ) ; 1.18-1.61(m,12H), 2.82-3.08(m,2H), 4.22- 4.38(m,3H), 4.45(d,2H), 5.01(d,lH), 7.02-7.45(m,5H), 8.25(s,lH). Example 15 O-(N-Ethoxycarbonyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(L)-phenylalaninol The procedure given in Example 14 was followed using N-(t-butyloxycarbonyl)- (L)-phenylalaninol as a starting material, instead of N-(t-butyloxycarbonyl)-(D)- phenylalaninol, to give 3.4g ofthe title compound. A yield of 64%> was obtained. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 1.18-1.48(m,12H), 2.85-3.01(m,2H), 4.22- 4.32(m,3H), 4.45(d,2H), 5.01(d,lH), 7.12-7.35(m,5H), 8.28(s,lH). Example 16 3-N-(t-Butyloxycarbonyl)amino-3-phenyl-l-O-((N-methyl)thiocarbamoyl) propanol The procedure given in Example 1 was followed using 3-N-(t- butyloxycarbonyl)amino-3-phenyl-l -propanol as a starting material and methyl amine as a reactant instead of N-(t-butyloxycarbonyl)-(DL)-phenylalaninol and NH OH to give 3 -N-(t-butyloxycarbonyl) amino-3 -phenyl- 1 -O-((N-methyl)thiocarbamoyl) propanol. A yield of 70% was obtained. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 1.18-1.48(m,9H), 2.68-32.92(m,3H), 3.02(d,2H), 4.01-4.18(m,lH), 4.29-4.48(m,2H), 4.85-4.92(m,lH), 6.81(br.,0.4H), 7.05- 7.31(m,5H), 7.42(br.,0.6H). Example 17 3-N-(t-Butyloxycarbonyl)amino-2-phenyl- 1 -O-(thiocarbamoyl)propanol The procedure given in Example 1 was followed using 3-N-(t- butyloxycarbonyl)amino-2-phenyl-l -propanol as a starting material instead of N-(t- butyloxycarbonyl)-(DL)-phenylalaninol, to give 3-N-(t-butyloxycarbonyl)amino-2- phenyl- l-O-(thiocarbamoyl) propanol. A yield of 66% was obtained. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 1.42 (s, 9H), 3.21-3.40 (m, 2H), 3.55-3.68 (m, 1H), 4.50-4.70 (m, 3H), 6.20 (bs, 1H), 6.42 (bs, 1H), 7.20-7.40 (m, 5H) Example 18 3-N-(t-Butyloxycarbonyl)amino-2-phenyl- 1 -O-((N-methly)thiocarbamoyl) propanol The procedure given in Example 1 was followed using 3-N-(t- butyloxycarbonyl)amino-2-phenyl-l -propanol as a starting material and methyl amine as a reactant instead of N-(t-butyloxycarbonyl)-(DL)-phenylalaninol and NH OH to give 3 -N-(t-butyloxycarbonyl)amino-2-phenyl- 1 -O-((N-methyl)thiocarbamoyl) propanol. A yield of 92% was obtained. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 1.40 (9H), 2.89 (1H), 3.06 (H), 3.13- 3.45(2H), 3.45-3.72 (1H), 4.40-5.80 (2H), 6.30-6.70 (1H), 7.10-7.40 (5H) Example 19 3-N-(t-Butyloxycarbonyl)amino-2-phenyl-l-O-((N-dimethyl)thiocarbamoyl) propanol The procedure given in Example 1 was followed using 3-N-(t- butyloxycarbonyl)amino-2 -phenyl- 1 -propanol as a starting material and dimethyl amine as a reactant instead of N-(t-butyloxycarbonyl)-(DL)-phenylalaninol and NH 4 OH to give 3-N-(t-butyloxycarbonyl) amino-2-phenyl-l-O-((N-dimethyl)thiocarbamoyl) propanol. A yield of 65% was obtained. ■ H-NMR(CDC1 3 , 200MHz), ppm(δ) ; 1.41 (s, 9H), 3.01 (s, 3H), 3.33 (3, 3H), 3.20-3.45 (m, 2H), 3.60 (m, 1H), 4.55-4.70 (m, 3H), 7.20-7.40 (m, 5H) Example 20 O-(N-Methyl)thiocarbamoyl-N-dimethyl-(D)-phenylalaninol The procedure given in Example 3 was followed using N-dimethyl-D- phenylalaninol as a starting material and methylamine as a reactant, instead of N-(t- butyloxycarbonyl)-(D)-phenylalaninol and NH 4 OH, to give 3.52g of the title compound. A yield of 92% was obtained. ιH-NMR(CDCl 3 , 200MHz), ppm(δ) ; 2.35(s,7.6H), 2.65-2.82(m,1.4H), 2.85- 3.18(m,3H), 4.25-4.59(m,2H), 6.55(br,0.76H), 6.75(br,0.14H), 6.98-7.32(m,5H). Example 21 O-Thiocarbamoyl-(DL)-phenylalaninol Hydrochloride In a lOOmL flask equipped with magnetic stirrer, O-thiocarbamoyl-N-(t- butyloxycarbonyl)-(DL)-phenylalaninol obtained in Example 1 was dissloved in 40mLof THF and was added with 20mL of 6N aqueous hydrochloric acid solution. The reaction mixture was stirred at room temperature for 8 hours, followed by the neutralization with saturated aqueous potassium carbonate solution. Thereafter, the organic layer was extracted 3 times with dichloromethane, dried over magnesium sulfate and distilled in vacuo, to give a yellowish liquid. This was dissolved in 30mL of THF and added with anhydrous hydrochloric acid at 0°C, to obtained desirable white precipitates. To this was added 30mL of anhydrous diethyl ether, with the aim of maximizing the precipitation. As a result, 1.32g of the title compound was obtained: Yield 82%. Melting point : 181.3 - 181.6 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.78-3.18(m,2H), 3.78-4.02(m,lH), 4.15(d-d,lH), 4.37(d-d,lH), 7.08-7.45(m,5H), 8.38(br,4H), 9.02(s,lH). Example 22 O-Thiocarbamoyl-(L)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-thiocarbamoyl -N-(t- butyloxycarbonyl)-(L)-phenylalaninol as a starting material, to give the title compound. Melting point : 173.2 - 173.6 °C ιH-NMR(DMSO-d 6) 200MHz), ppm(δ) ; 2.78-3.15(m,2H), 3.58-3.82(br,lH), 4.15(d-d,lH), 4.35(d-d,lH), 7.02-7.43(m,5H), 8.45(br,4H), 9.01(s,lH). Example 23 O-Thiocarbamoyl-(D)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-thiocarbamoyl -N-(t- butyloxycarbonyl)-(D)-phenylalaninol as a starting material, to give the title compound. Melting point : 181.5 - 181.7 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.78-3.22(m,2H), 3.58-3.82(br,lH), 4.08-4.48(m,2H), 7.12-7.58(m,5H), 8.45(br,4H), 9.05(s,lH). Example 24 O-(N-Methyl)thiocarbamoyl-(D)-ρhenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N- methyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol as a starting material, to give the title compound. Melting point : 178.1 - 179.5 °C ,H-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.75-3.25(m,5H), 3.65-3.95(br,lH), 4.11-4.55(m,2H), 7.18-7.6 l(m,5H), 7.48(br,3H), 9.25(d-d,lH). Example 25 O-(N-Cyclopropyl)thiocarbamoyl-(D)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N-cyclopropyl) thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol as a starting material, to give the title compound. Melting point : 180 - 181 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 0.45-0.9 l(m,4H), 2.80-3.26(m,3H), 3.62-3.92(m,lH), 4.15-4.61(m,2H), 7.18-7.58(m,5H), 8.45(br,3H), 9.45(d-d,lH). Example 26 O-(N-Octyl)thiocarbamoyl-(D)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N- octyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol as a starting material, to give the title compound. Melting point : 123 - 124 °C !H-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 0.89(t,3H), 1.12-1.68(m,14H), 2.78- 3.35(m,4H), 3.75(br,lH), 4.01-4.82(m,4H), 7.05-7.48(m,5H), 8.52(br,3H), 9.32(d- d,lH). Example 27 O-(N-Isopropyl)thiocarbamoyl-(D)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N-isopropyl) thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol as a starting material, to give the title compound. Melting point : 200.1 - 201 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 1.05-1.45(m,6H), 2.82-3.22(m,2H), 3.62-3.92(m,lH), 4.05-4.55(m,3H), 7.18-7.58(m,5H), 8.45(br,3H), 9.25(t,lH). Example 28 O-(N-Dimethyl)thiocarbamoyl-(D)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N-dimethyl) thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol as a starting material, to give the title compound. Melting point : 185.6 - 186.4 °C ' ,H-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.75-3.55(m,7H), 3.99(br.s,lH), 4.12- 4.58(m,2H), 7.11-7.58(m,5H), 8.65(br,3H). Example 29 O-(N-Mo holino)thiocarbamoyl-(D)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N-morpholino) thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol as a starting material, to give the title compound. Melting point : 202 - 203 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.78-3.18(m,2H), 3.38-4.08(m,l lH), 4.18-4.53(m,2H), 7.18-7.48(m,5H), 8.41(br,3H). Example 30 O-Thiocarbamoyl-(D)-(p-hydroxy)phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-thiocarbamoyl-N-(t- butyloxycarbonyl)-(D)-(p-t-butyloxycarbonyloxy)phenylalaninol as a starting material, to give the title compound. Melting point : 173.8 - 175.4 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.68-3.18(m,2H), 3.38-3.81(m,lH), 3.90-4.5 l(m,2H), 6.45-7.22(m,4H), 8.35(br,3H), 9.01(s,lH), 9.41(s,lH). Example 31 O-(N-Dimethyl)thiocarbamoyl-(D)-(3 ,4-dichloro)phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N-dimethyl) thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-(m,p-dichloro)phenylalaninol as a starting material, to give the title compound. Melting point : 189.7 - 190.3 °C ,H-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.82-3.48(m,8H), 3.72-3.94(m,lH), 4.25-4.59(m,2H), 7.32(d,lH), 7.52-7.75(m,2H), 8.35(br,3H). Example 32 O-(N-Methyl)thiocarbamoyl-(DL)-(o-fluoro)phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N- methyl)thiocarbamoyl-N-(t-butyloxycarbonyl)-(DL)-(o-fluoro)phenylalaninol as a starting material, to give the title compound. Melting point : 169.6 - 170.2 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.78(d-d,3H), 2.85-3.22(m,2H), 3.62- 3.81(m,lH), 4.18(d-d,lH), 4.46(d-d,lH), 6.98-7.48(m,4H), 8.45(br,3H), 9.20(d-d,lH). Example 33 O-Thiocarbamoyl-(DL)-(p-chloro)phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-thiocarbamoyl-N-(t- butyloxycarbonyl)-(DL)-(p-chloro)phenylalaninol as a starting material, to give the title compound. Melting point : 187.5 - 187.7 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.82-3.15(m,2H), 3.62-3.82(m,lH), 4.18(d-d,lH), 4.39(d-d,lH), 7.18-7.49(m,4H), 8.45(br,4H), 9.01(s,lH). Example 34 O-(N-Ethoxycarbonyl)thiocarbamoyl-(D)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N-ethoxyxcarbonyl) thiocarbamoyl-N-(t-butyloxycarbonyl)-(D)-phenylalaninol as a starting material, to give the title compound. Melting point : 157 - 157.8 °C ! H-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 1.22(t,3H), 2.78-3.18(m,2H), 3.82(br,lH) 4.22(q,3H), 4.58(d-d,lH), 7.18-7.45(m,5H), 8.42(br,3H), 11.78(s,lH). Example 35 O-(N-Ethoxycarbonyl)thiocarbamoyl-(L)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N-ethoxycarbonyl) thiocarbamoyl-N-(t-butyloxycarbonyl)-(L)-phenylalaninol as a starting material, to give the title compound. Melting point : 144.4 - 145.0 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 1.22(t,3H), 2.78-3.18(m,2H), 3.62- 3.92(m,lH), 3.95-4.38(m,3H), 4.42-4.62(m,lH), 7.02-7.45(m,5H), 8.42(br,3H), 11.85(s,lH). Example 36 3 -Amino-3 -phenyl- 1 -(O-(N-methyl)thiocarbamoyl)propanol Hydrochloride The procedure given in Example 21 was followed using 3-N-(t- Butyloxycarbonyl) amino-3-phenyl-l-O-((N-methyl)thiocarbamoyl)-propanol as a starting material, to give the title compound. Melting Point : 182.1 - 182.4 °C ,H-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.71-3.12(m,3H), 3.22-3.48(m,2H), 3.75-3.95(m,lH), 4.18-4.62(m,2H), 7.25-7.62(m,5H), 8.25(br.,3H), 9.20(d,lH). Example 37 3-Amino-2-phenyl- 1 -(O-thiocarbamoyl)propanol Hydrochloride The procedure given in Example 21 was followed using 3-N-(t- butyloxycarbonyl) amino-2-phenyl-l-O-(thiocarbamoyl)propanol as a starting material, to give the title compound. Melting Point : 189.5-190.0 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 3.05-3.50 (m, 3H), 4.35-4.55 (m, 2H), 7.30 (s, 5H), 7.95 (bs, 3H), 8.53 (s, 1H), 8.85 (s, 1H). Example 38 3-Amino-2-phenyl- 1 -O-((N-methyl)thiocarbamoyl)propanol Hydrochloride The procedure given in Example 21 was followed using 3-N-(t- butyloxycarbonyl) amino-2-phenyl-l-O-((N-methyl)thiocarbamoyl)-propanol as a starting material, to give the title compound. Melting Point : 95.0-96.0 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.60 (d, 0.6H), 2.86 (d, 2.4 H), 3.07- 3.48 (m, 3H), 4.39-4.63 (m, 2H), 7.37 (s, 5H), 8.10 (bs, 3H), 9.15 (bs, 0.2H), 9.30 (bs, 0.8 H) Example 39 3 -Amino-2 -phenyl- 1 -O-((N-dimethyl)thiocarbamoyl)propanol Hydrochloride The procedure given in Example 21 was followed using 3-N-(t- butyloxycarbonyl)-amino-2-phenyl- 1 -O-((N-dimethyl)thiocarbamoyl)propanol as a starting material, to give the title compound. Melting Point : 164.1-164.6 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.98 (s, 3H), 3.22 (s, 3H), 3.30-3.60 (m, 3H), 4.53 (m, 2H), 7.37 (m, 5H), 8.13 (bs, 3H) Example 40 O-(N-Methyl)thiocarbamoyl- N-dimethyl-(D)-phenylalaninol Hydrochloride The procedure given in Example 21 was followed using O-(N-methyl) thiocarbamoyl-N-dimethyl-(D)-phenylalaninol as a starting material, to give the title compound. Melting point : 152.5 - 152.7 °C ιH-NMR(DMSO-d 6 , 200MHz), ppm(δ) ; 2.55-3.15(m,9H), 3.15-3.45(m,2H), 3.75-4.02(m,lH), 4.15-4.71(m,2H), 7.05-7.58(m,5H), 9.25-9.65(m,lH), 11.05(br,lH). The present invention has been described in an illustrative manner, and it is to be understood that the terminology used herein is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

Claims: WHAT IS CLAIMED IS: 1. A racemic or enantiomerically enriched O-Thiocarbamoyl-aminoalkanol compound represented by the following structural formula (VI): wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3, Ri and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and t may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and R 4 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected each of 1, m and n is zero or 1 , and the pharmaceutically acceptable salts thereof. 2. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (VI), in accordance with claim 1, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 3. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (VI), in accordance with claim 1, wherein R is hydrogen, Rj and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atom directly unconnected, R 3 and R_t may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and Rj, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atom directly unconnected, and the pharmaceutically acceptable salts thereof. 4. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (VI), in accordance with claim 1, wherein x is 1, and the pharmaceutically acceptable salts thereof. 5. An enantiomerically enriched O-Thiocarbamoyl-(D)-aminoalkanol compound represented by the following structural formula (VIII): wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3, Ri and R may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R_t may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and Rt, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, each of 1, m and n is zero or 1 , and the pharmaceutically acceptable salts thereof. 6. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (VIII), in accordance with claim 5, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 7. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (VIII), in accordance with claim 5, wherein R is hydrogen, Rj and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atom directly unconnected, R 3 and j may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and R 4 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 8. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (VIII), in accordance with claim 5, wherein x is 1, and the pharmaceutically acceptable salts thereof. 9. An enantiomerically enriched O-Thiocarbamoyl-(L)-aminoalkanol compound represented by the following structural formula (IX) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3, Ri and R may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R \ and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and Rj may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and, R and i together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atom substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, each of 1, m and n is zero or 1 , and the pharmaceutically acceptable salts thereof. 10. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (IX), in accordance with claim 9, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 11. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (IX), in accordance with claim 9, wherein R is hydrogen, Rj and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Rj and R , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and Rj may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and R 4 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 12. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (IX), in accordance with claim 9, wherein x is 1, and the pharmaceutically acceptable salts thereof. 13. A racemic or enantiomerically enriched O-Thiocarbamoyl-aminoalkanol compound represented by the following structural formula (X) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Rj and R 2) together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and * may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and R4, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 14. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (X), in accordance with claim 13, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 15. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (X), in accordance with claim 13, wherein R is hydrogen, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R 4 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and 4 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 16. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (X), in accordance with claim 13, wherein x is 1, and the pharmaceutically acceptable salts thereof. 17. An enantiomerically enriched O-Thiocarbamoyl-(D)-aminoalkanol compound represented by the following structural formula (XI) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R* may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and ^, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 18. O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XI), in accordance with claim 17, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 19. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XI), in accordance with claim 17, wherein R is hydrogen, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Rj and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and j may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and j, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 20. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XI), in accordance with claim 17, wherein x is 1, and the pharmaceutically acceptable salts thereof. 21. An enantiomerically enriched O-Thiocarbamoyl-(L)-aminoalkanol compound represented by the following structural formula (XII) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R_j may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and R>, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 22. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XII), in accordance with claim 21, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 23. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XII), in accordance with claim 21, wherein R is hydrogen, Ri and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R4 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and R t , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 24. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XII), in accordance with claim 21, wherein x is 1, and the pharmaceutically acceptable salts thereof. 25. A racemic or enantiomerically enriched O-Thiocarbamoyl-aminoalkanol compound represented by the following structural formula (XIII) : wherein Ar is a phenyl group as described as follows: wherein R is a meymber selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Rj and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R] and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R t may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and j, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected , and the pharmaceutically acceptable salts thereof. 26. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XIII), in accordance with claim 25, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 27. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XIII), in accordance with claim 25, wherein R is hydrogen, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R» may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and R_j, together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 28. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XIII), in accordance with claim 25, wherein x is 1, and the pharmaceutically acceptable salts thereof. 29. An enantiomerically enriched O-Thiocarbamoyl-(D)-aminoalkanol compound represented by the following structural formula (XIV) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Rj and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R_» may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and R_t, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected , and the pharmaceutically acceptable salts thereof. 30. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XIV), in accordance with claim 29, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 31. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XIV), in accordance with claim 29, wherein R is hydrogen, Rj and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R\ and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and j may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and R_j, together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 32. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XTV), in accordance with claim 29, wherein x is 1, and the pharmaceutically acceptable salts thereof. 33. An enantiomerically enriched O-Thiocarbamoyl-(L)-aminoalkanol compound represented by the following structural formula (XV) : (XV) wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Rj and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R 4 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and Rt, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected , and the pharmaceutically acceptable salts thereof. 34. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XV), in accordance with claim 33, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 35. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XV), in accordance with claim 33, wherein R is hydrogen, Rj and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R_» may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and *, together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 36. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XV), in accordance with claim 33, wherein x is 1, and the pharmaceutically acceptable salts thereof. 37. A racemic or enantiomerically enriched O-Thiocarbamoyl-aminoalkanol compound represented by the following structural formula (XVI): wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Rj and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R 4 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and R_t, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 38. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XVI), in accordance with claim 37, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 5 39. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XVI), in accordance with claim 37, wherein R is hydrogen, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and and R , together with the adjoining N-atom, form a 5 to 7- 10 membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic 15 cyclic compounds and R 3 and t , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. ' 20 40. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XVI), in accordance with claim 37, wherein x is 1, and the pharmaceutically acceptable salts thereof. 25 41. An enantiomerically enriched O-Thiocarbamoyl-(D)-aminoalkanol compound represented by the following structural formula (XVII) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Rj and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and j may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and j, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 42. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XVII), in accordance with claim 41, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 43. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XVII), in accordance with claim 41, wherein R is hydrogen, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Rj and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and R 4 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R and R_t, together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 44. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XVII), in accordance with claim 41, wherein x is 1, and the pharmaceutically acceptable salts thereof. 45. An enantiomerically enriched O-Thiocarbamoyl-(L)-aminoalkanol compound represented by the following structural formula (XVIII) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Ri and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and j may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon a * toms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and P , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 46. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XVIII), in accordance with claim 45, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 47. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XVIII), in accordance with claim 45, wherein R is hydrogen, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and j may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and R_j, together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 48. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XVIII), in accordance with claim 45, wherein x is 1, and the pharmaceutically acceptable salts thereof. 49. A racemic or enantiomerically enriched O-Thiocarbamoyl-aminoalkanol compound represented by the following structural formula (XIX) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Ri and R may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and j may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and R , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 50. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XIX), in accordance with claim 49, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 51. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XIX), in accordance with claim 49, wherein R is hydrogen, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R\ and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and } may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and t , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 52. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XIX), in accordance with claim 49, wherein x is 1, and the pharmaceutically acceptable salts thereof. 53. An enantiomerically enriched O-Thiocarbamoyl-(D)-aminoalkanol compound represented by the following structural formula (XX) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Ri and R may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and t may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R 3 and Rt, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 54. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XX), in accordance with claim 53, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 55. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XX), in accordance with claim 53, wherein R is hydrogen, Ri and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and t may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and t, together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. ' 56. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XX), in accordance with claim 53, wherein x is 1, and the pharmaceutically acceptable salts thereof. 57. An enantiomerically enriched O-Thiocarbamoyl-(L)-aminoalkanol compound represented by the following structural formula (XXI) : wherein Ar is a phenyl group as described as follows: wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br, and I, alkoxy containing 1 to 3 carbon atoms, thioalkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, or trifluorocarbon, and x is an integer from 1 to 3, with the proviso that R is the same or different when x is 2 or 3. Ri and R 2 may be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and t may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, 3 to 7-membered aliphatic cyclic compounds and R and Rt, together with the adjoining N-atom, form a 5 to 7-membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 58. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XXI), in accordance with claim 57, wherein R is hydrogen, and the pharmaceutically acceptable salts thereof. 59. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XXI), in accordance with claim 57, wherein R is hydrogen, R ! and R 2 may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and Ri and R 2 , together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, R 3 and t may be same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, 3 to 7-membered aliphatic cyclic compounds and R 3 and Rt, together with the adjoining N-atom, form a 5 to 7- membered cyclic compound which optionally comprises zero to one additional nitrogen atoms substituted with a member selected from the group consisting of hydrogen, alkyl and aryl groups, or zero to one oxygen atoms directly unconnected, and the pharmaceutically acceptable salts thereof. 60. The O-Thiocarbamoyl-aminoalkanol compound represented by the structural formula (XXI), in accordance with claim 57, wherein x is 1, and the pharmaceutically acceptable salts thereof. 61. A method for the preparation of a compound of formula (VI) as defined in claim 1, in which an aminoalkanol of general formula (II) (II) is reacted with Di-t-butyl dicarbonate to synthesize N-t-butyloxycarbonyl- aminoalkanol represented by the formula (III), (III) followed by the treatment with sodium hydride, carbon disulfide and methyl iodide in an etheral solution, which is followed by the treatment with an amine compound of formula (IV) HNRjR. 2 ( iv; to yield O-thiocarbamoyl-N-t-butyloxycarbonyl- aminoalkanol represented by general formula(V), (V) wherein Ar, Ri, R 2 , R 3 ' R t , 1, m and 'n are as defined above claim 1 and Boc repressants t-butyloxy carbonyl radical, which is deprotected by aqueous hydrochloric acid solution to give a O-thiocarbamoyl-aminoalkanol represented by the general formula (VI). (VI) 62. The method of claim 61 wherein without further purification, the compound of formula (VI) may be converted into its pharmaceutically acceptable salts, formula (I) 63. A method for the preparation of a compound of formula (VI) wherein as defined in claim 1 , in which an aminoalkanol of general formula (II) wherein R 3 and t are not hydrogen (II) is reacted with sodium hydride, carbon disulfide and methyl iodide in an etheral solution which is followed by the treatment with an amine compound of formula (IV) HNRjR. 2 ( iv: to yield O-thiocarbamoyl-aminoalkanol represented by the general formula (VI). (VI) 64. The method of claim 63 wherein without further purification, the compound of formula (VI) may be converted into its pharmaceutically acceptable salts, formula (I) 65. A method for the preparation of a compound of formula (VI) as defined in claim 1, in which an aminoalkanol of general formula (II) wherein Rι=H (II) is reacted with Di-t-butyl dicarbonate to synthesize N-t-butyloxycarbonyl- aminoalkanol represented by the formula (III), (HI) followed by the treatment with isothiocyanate compound of formula (VII) R 2 NCS (VII) in an halogenated hydrocarbon solution to yield O-thiocarbamoyl-N-t- butyloxycarbonyl-aminoalkanol represented by general formula (V), (V) wherein Ar, Ri, R 2 , R 3 ' R t , 1, m and n are as defined above claim 1 and Boc repressants t-butyloxy carbonyl radical, which is deprotected by aqueous hydrochloric acid solution to give a O-thiocarbamoyl-aminoalkanol represented by the general formula (VI). (VI) 66. The method of claim 65 wherein without further purification, the compound of formula (VI) may be converted into its pharmaceutically acceptable salts, formula (I) 67. A method for the preparation of a compound of formula (VI) wherein as defined in claim 1 , in which an aminoalkanol of general formula (II) wherein R 3 and t are not hydrogen (II) is reacted with isothiocyanate compound of formula (VII) R 2 NCS (VII) in an halogenated hydrocarbon solution to yield a O-thiocarbamoyl- aminoalkanol represented by the general formula (VI). (VI) 68. The method of claim 67, wherein without further purification, the compound of formula (VI) may be converted into its pharmaceutically acceptable salts, formula (I) 69. A method for the preparation of a compound of formula (VIII) according to claim 61 in which an (D)-aminoalkanol is employed. 70. A method for the preparation of a compound of formula (VIII) according to claim 63 in which an (D)-aminoalkanol is employed 71. A method for the preparation of a compound of formula (VIII) according to claim 65 in which an (D)-aminoalkanol is employed 72. A method for the preparation of a compound of formula (VIII) according to claim 67 in which an (D)-aminoalkanol is employed 73. A method for the preparation of a compound of formula (IX) according to claim 61 in which an (L)-aminoalkanol is employed. 74. A method for the preparation of a compound of formula (VIII) according to claim 63 in which an (L)-aminoalkanol is employed 75. A method for the preparation of a compound of formula (VIII) according to claim 65 in which an (L)-aminoalkanol is employed 76. A method for the preparation of a compound of formula (VIII) according to claim 67 in which an (L)-aminoalkanol is employed 77. A pharmaceutical composition, comprising a compound of formula (VI) or a pharmaceutically acceptable salt thereof as claimed in claimel, together with a non- toxic pharmaceutically acceptable carrier or diluent therefor. 78. A pharmaceutical composition, comprising a compound of formula (VIII) or a pharmaceutically acceptable salt thereof as claimed in claime 5, together with a non- toxic pharmaceutically acceptable carrier or diluent therefor. 79. A pharmaceutical composition, comprising a compound of formula (IX) or a pharmaceutically acceptable salt thereof as claimed in claim 9, together with a non- toxic pharmaceutically acceptable carrier or diluent therefor. 80. A method of treating a mammal suffering from a disorder of the central nervous system which comprises adminstering to said mammal a central nervous system dosage effective amount ofthe compound of claim 1. 81. A method of treating a mammal suffering from a disorder of the central nervous system which comprises adminstering to said mammal a central nervous system dosage effective amount of the compound of claim 5. 82. A method of treating a mammal suffering from a disorder of the central nervous system which comprises adminstering to said mammal a central nervous system dosage effective amount ofthe compound of claim 9. 83. A compound selected from the group consisting of O-Thiocarbamoyl-(DL)- phenylalaninol, O-Thiocarbamoyl-(D)-phenylalaninol, and O-Thiocarbamoyl-(L)- phenylalaninol; and non-toxic pharmacologically acceptable salts thereof. 84. O-Thiocarbamoyl-(D)-ρhenylalaninol; and non-toxic pharmacologically acceptable salts thereof. 85. O-Thiocarbamoyl-(L)-phenylalaninol; and non-toxic pharmacologically acceptable salts thereof. 86. A method of treating a mammal suffering from disorder of the central nervous system which comprises administering to said mammal a central nervous system dosage effective amount ofthe compound of claim 83. 87. A method of treating a mammal suffering from disorder of the central nervous system which comprises administering to said mammal a central nervous system dosage effective amount of the compound of claim 84. 88. A method of treating a mammal suffering from disorder of the central nervous system which comprises administering to said mammal a central nervous system dosage effective amount ofthe compound of claim 85.

Inventors: CHOI YONG MOON, KIM YONG KIL, CHOI, YONG, MOON, KIM, YONG, KIL
Applicants: SK CORP, SK CORPORATION
Application year: 1999
Main classification: C07C333
IPC codes: A61K31, A61P25, C07C333, C07D295